Free Trial

Pfizer (PFE) Earnings Date, Estimates & Call Transcripts

Pfizer logo
$26.36 +0.59 (+2.29%)
(As of 12/20/2024 05:45 PM ET)

Pfizer Latest Earnings Summary

Latest Q3 2024
Earnings Date
Oct. 29Confirmed
Actual EPS
(Oct. 29)
$1.06 Beat By $0.42
Consensus EPS
(Oct. 29)
$0.64

Pfizer announced Q3 2024 earnings on October 29, 2024, reporting an EPS of $1.06, which beat analysts' consensus estimates of $0.64 by $0.42. Quarterly revenue rose 31.2% year-over-year to $17.70 billion, above analyst estimates of $14.92 billion. With a trailing EPS of $0.74 and a P/E Ratio of 35.62, Pfizer's earnings are expected to decrease -1.69% next year, from $2.95 to $2.90 per share.

Get Pfizer Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pfizer and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

PFE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PFE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Pfizer Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243$0.50$1.02$0.69 
Q2 20243$0.43$0.82$0.58 
Q3 20243$0.57$0.82$0.69 
Q4 20243$0.39$1.06$0.69 
FY 202412$1.89$3.72$2.65 
Q1 20252$0.58$0.68$0.63 
Q2 20252$0.55$0.59$0.57 
Q3 20252$0.72$1.11$0.92 
Q4 20252$0.66$0.81$0.74 
FY 20258$2.51$3.19$2.85 
Q1 20261$0.71$0.71$0.71 
Q2 20261$0.63$0.63$0.63 
Q3 20261$0.78$0.78$0.78 

Pfizer Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/29/2024Q3 2024$0.64$1.06+$0.42$1.34$14.92B$17.70B
7/30/2024Q2 2024$0.46$0.60+$0.14$1.19$12.96B$13.28B
5/1/2024Q1 2024$0.56$0.82+$0.26$1.09$13.87B$14.88B
1/30/2024Q4 2023-$0.19$0.10+$0.29$0.80$14.37B$14.25B
10/31/2023Q3 2023-$0.32-$0.17+$0.15$0.08$13.77B$13.23B
8/1/2023Q2 2023$0.57$0.67+$0.10$0.93$13.36B$12.73B
5/2/2023Q1 2023$1.00$1.23+$0.23$1.49$16.49B$18.28B
1/31/2023Q4 2022$1.03$1.14+$0.11$1.41$24.40B$24.30B

Pfizer Earnings - Frequently Asked Questions

Pfizer (NYSE:PFE) last announced its quarterly earning data on Tuesday, October 29, 2024. Learn more on PFE's earnings history.

Pfizer issued an update on its FY 2024 earnings guidance on Wednesday, December, 18th. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus estimate of 2.930. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $62.9 billion.

In the previous quarter, Pfizer (NYSE:PFE) reported $1.06 earnings per share (EPS) to beat the analysts' consensus estimate of $0.64 by $0.42. Learn more on analysts' earnings estimate vs. PFE's actual earnings.

The conference call for Pfizer's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Pfizer's latest earnings report can be read online.
Read Transcript

Pfizer (NYSE:PFE) has a recorded annual revenue of $59.38 billion.

Pfizer (NYSE:PFE) has a recorded net income of $2.12 billion. PFE has generated $0.74 earnings per share over the last four quarters.

Pfizer (NYSE:PFE) has a trailing price-to-earnings ratio of 35.62 and a forward price-to-earnings ratio of 8.94. The price/earnings-to-growth ratio is 0.63.

Pfizer's earnings are expected to decrease from $2.95 per share to $2.90 per share in the next year, which is a -1.69% change.

More Earnings Resources from MarketBeat



This page (NYSE:PFE) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners